EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Factors Associated With Perceived Cognitive Dysfunction in Patients With Primary Brain Tumors: The Utility of the Neuro‐ QoL Cognition Function Scale

Morgan Johnson, Kimberly Reinhart, Vivian A Guedes, Michelle L Wright iD, Elizabeth Vera, Alvina Acquaye-Mallory iD, Hope Miller, Anna Choi, Tricia Kunst, Jennifer Reyes, Jing Wu, Marta Penas-Prado und 5 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72203 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Morgan Johnson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Cognition, Cognitive Dysfunction, Quality of Life. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary brain tumor (PBT) patients commonly experience cognitive dysfunction. This study aims to describe the prevalence and factors associated with perceived cognitive function (PCF) in PBT patients enrolled in a natural history study (NCT02851706: Principal Investigator T. S. Armstrong).

Methods

The Neuro‐QoL Cognition Function was used to measure PCF with T‐scores < 40 categorized as cognitively impaired. Clinical and demographic characteristics, patient‐reported outcomes (PROs: symptom burden, depression, anxiety), and KPS were collected and characterized using descriptive statistics. Univariate tests on PCF with p ‐value < 0.10 were performed and included in a subsequent multivariate logistic regression with backward selection. Clinical variables and PROs were evaluated separately, then combined for a final multivariate model with p ‐value < 0.05.

Results

The cohort included 327 patients (median age: 47 years [range: 18–85], primarily white [78%] males [55%] with high‐grade tumors [73%]). Perceived cognitive impairment occurred in 29% of patients. Patients presenting with cognitive dysfunction at diagnosis, or who had undergone multiple surgeries, were more likely to have poor PCF, as were those currently on corticosteroids and reporting cognitive symptoms and symptom interference. Evaluated together, a multivariate model found that only higher scores on symptom interference and the cognitive symptom factor increased the likelihood of cognitive impairment (symptom interference odds ratio [OR] = 1.25, 95% confidence interval [CI] [1.09, 1.44], p < 0.001; cognitive symptom factor OR = 1.81, 95% CI [1.50, 2.19], p < 0.001) with an 84% classification rate.

Conclusions

Self‐reported cognitive symptoms and interference were the strongest patient‐reported correlates of PCF and should be interpreted as concurrent associations among related constructs. Further psychometric and longitudinal work is needed to clarify the incremental clinical value of the Neuro‐QoL Cognition Function Short Form in PBT care and research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCognitionCognitive DysfunctionQuality of LifeAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultNeuropsychological TestsPatient Reported Outcome MeasuresSymptom Burden

Stichwörter der Autor:innen

cognitive dysfunctionneuro‐QoLpatient‐reported outcomesprimary brain tumorsymptoms

Autor:innen und Institutionen

  • Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Office of Patient-Centered Outcomes Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Michelle L Wright, Alvina Acquaye-Mallory

Förderung

  • Intramural NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Johnson, M., Reinhart, K., Guedes, V. A., Wright, M. L., Vera, E., Acquaye-Mallory, A., Miller, H., Choi, A., Kunst, T., Reyes, J., Wu, J., Penas-Prado, M., Ozer, B., Burton, E., Gilbert, M. R., Armstrong, T. S., & Mendoza, T. (2026). Factors Associated With Perceived Cognitive Dysfunction in Patients With Primary Brain Tumors: The Utility of the Neuro‐ QoL Cognition Function Scale. Cancer Medicine. https://doi.org/10.1002/cam4.72203

Vancouver

Johnson M, Reinhart K, Guedes VA, Wright ML, Vera E, Acquaye-Mallory A, et al. Factors Associated With Perceived Cognitive Dysfunction in Patients With Primary Brain Tumors: The Utility of the Neuro‐ QoL Cognition Function Scale. Cancer Medicine. 2026. doi:10.1002/cam4.72203

BibTeX
@article{Johnson2026,
  author = {Johnson, Morgan and Reinhart, Kimberly and Guedes, Vivian A and Wright, Michelle L and Vera, Elizabeth and Acquaye-Mallory, Alvina and Miller, Hope and Choi, Anna and Kunst, Tricia and Reyes, Jennifer and Wu, Jing and Penas-Prado, Marta and Ozer, Byram and Burton, Eric and Gilbert, Mark R and Armstrong, Terri S and Mendoza, Tito},
  title = {Factors Associated With Perceived Cognitive Dysfunction in Patients With Primary Brain Tumors: The Utility of the Neuro‐ QoL Cognition Function Scale},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72203}
}
Kostenlos starten →